TLX News: Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate - 11th Apr 2023, 7:00am

[annb0t]

MELBOURNE, Australia, April 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a Phase I study of TLX101 investigational therapy (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in Chinese patients with newly diagnosed glioblastoma (GBM). (PRNewsfoto/Telix Pharmaceuticals Limited)

The investigational new drug (IND) application was submitted ...

>>> Read more: Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate